Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is facing financial challenges, as evidenced by their recent modest $1M financing and the potential for future dilution as they continue to fund clinical development and other operational needs. However, their strategic value remains strong, particularly with the exclusive Emory license for Gedeptin and the ongoing global transmission concerns for mpox. Although the potential for near-term share price support is low, the company is aiming for a pivotal year in 2026 with multiple clinical readouts and regulatory de-risking, which could position them for success in the future.

Bears say

Geovax Labs is facing challenges with a secondary pipeline that is unlikely to provide significant value in the near term. The company's efforts to develop potential vaccines for infectious diseases and solid tumor cancer are still far from generating substantial revenue. Furthermore, recent reverse stock split and potential future capital raises may bring heightened dilution risk and investor sensitivity. Even though the company's most advanced program, GEO-MVA, has received positive feedback, commercialization and potential revenue generation are still years away.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.